Remogliflozin etabonate

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Remogliflozin etabonate
Remogliflozin etabonate structure.svg
Systematic (IUPAC) name
5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1H-pyrazol-3-yl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside
Clinical data
Routes of
administration		 Oral
Identifiers
CAS Number 442201-24-3 YesY
ATC code none
ChemSpider 8047110
UNII TR0QT6QSUL N
KEGG D10055 N
ChEMBL CHEMBL494323 N
Chemical data
Formula C26H38N2O9
Molecular mass 522.586 g/mol
  • OC1C(COC(=O)OCC)OC(C(O)C1O)Oc(nn(C(C)C)c2C)c2Cc3ccc(cc3)OC(C)C
  • InChI=1S/C26H38N2O9/c1-7-33-26(32)34-13-20-21(29)22(30)23(31)25(36-20)37-24-19(16(6)28(27-24)14(2)3)12-17-8-10-18(11-9-17)35-15(4)5/h8-11,14-15,20-23,25,29-31H,7,12-13H2,1-6H3/t20-,21-,22+,23-,25+/m1/s1
  • Key:UAOCLDQAQNNEAX-ABMICEGHSA-N
 NYesY (what is this?)  (verify)

Remogliflozin etabonate (INN/USAN)[1] is a proposed drug of the gliflozin class for the treatment of type 2 diabetes, investigated by GlaxoSmithKline.[2] Remogliflozin is now being developed by BHV Pharma with Islet Sciences.[3]

Clinical trials

Remogliflozin etabonate (RE) was shown to enhance urinary glucose excretion in rodents and humans. Early studies in diabetics improved plasma glucose levels.[4][5] Remogliflozin etabonate has been studied at doses up to 1000 mg.[6] A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin and that it was generally well tolerated.[7]

Method of action

Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[8] Remogliflozin is selective for SGLT2.

See also

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.
  1. ↑ Statement on a nonproprietory name adopted by the USAN council
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  4. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  7. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  8. ↑ Prous Science: Molecule of the Month November 2007[dead link]
Retrieved from "https://infogalactic.com/w/index.php?title=Remogliflozin_etabonate&oldid=5474073"